CG Oncology Inc
NASDAQ:CGON
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.59
45.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
CG Oncology Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
C
|
CG Oncology Inc
NASDAQ:CGON
|
3.3B USD |
-8 285%
|
|
| IL |
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
707T ILS |
-1 487%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
412.5B USD |
33%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.8B USD |
34%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
154.4B USD |
39%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123B USD |
39%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
85.5B USD |
28%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.5B AUD |
26%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
55.7B USD |
8%
|
CG Oncology Inc
Glance View
CG Oncology Inc. is navigating the turbulent waters of biotechnology with a laser focus on the treatment of bladder cancer. Rooted deeply in the realm of oncolytic immunotherapy, the company harnesses the power of genetically modified viruses to selectively infect and destroy cancer cells. Their flagship product, CG0070, is at the heart of this endeavor, utilizing a modified adenovirus that targets tumors after traditional treatments have failed or when they present a significant clinical challenge. This targeted approach not only aims to disrupt tumor growth directly but also to stimulate a broader immune response, turning the patient's own defenses against the malignant invaders. Commercial success in this niche is predicated on the ability to navigate a highly regulated space with lengthy clinical trials and significant investment in research and development. CG Oncology makes money by progressing its therapies through these clinical development stages, eventually securing regulatory approvals. The ultimate goal is to partner with larger pharmaceutical companies or independently bring their treatments to market, capitalizing on licensing agreements, sales, and milestone payments. This reflects a strategy commonly seen in the biotech sector, where innovation and partnerships drive revenue, turning cutting-edge science into viable, life-extending products for patients and profitable ventures for investors.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on CG Oncology Inc's most recent financial statements, the company has Operating Margin of -8 285.3%.